Suggested remit - To appraise the clinical and cost effectiveness of avelumab within its marketing authorisation for platinum-resistant and platinum-refractory ovarian cancer.
Following an update from the company this appraisal is now suspended.
Status Suspended
Decision Selected
Process TA

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
04 January 2019 Suspended. Following an update from the company this appraisal is now suspended.
15 November 2018 - 13 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 1497
22 November 2018 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of avelumab for previously treated platinum-resistant ovarian cancer ID1497 We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that markets avelumab has advised that they are no longer pursuing a licence in the UK for this product for this indication. In light of this information the Institute will not be progressing with the scoping exercise. If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar on (44 (0)20 7045 2239 or via email on
24 April 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual